These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Splenectomy in malignant hematological diseases]. Steruská M; Hrubisko M; Lipsic T; Schnorrer M; Cárský S Vnitr Lek; 1980 Oct; 26(10):951-7. PubMed ID: 7467147 [No Abstract] [Full Text] [Related]
3. [Management of chronic myeloproliferative disorders]. Ikkala E; Hormila P Duodecim; 1989; 105(11):1007-15. PubMed ID: 2473873 [No Abstract] [Full Text] [Related]
4. The selection of patients for splenectomy. Weatherall DJ Ann R Coll Surg Engl; 1971 Jan; 48(1):29. PubMed ID: 5572221 [No Abstract] [Full Text] [Related]
6. [Splenectomy in the light of current theories]. Urasiński I Pol Tyg Lek; 1982 Oct; 37(37):1109-12. PubMed ID: 6761663 [No Abstract] [Full Text] [Related]
7. Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease. Kraemer D; Rüdiger T; Reimer P; Müller-Hermelink HK; Wilhelm M Ann Hematol; 2002 Jun; 81(6):308-11. PubMed ID: 12107559 [TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder. El Kinge AR; Mahfouz RA; Shamseddine AI; Taher AT Blood Coagul Fibrinolysis; 2007 Sep; 18(6):577-9. PubMed ID: 17762536 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in biological and therapeutic aspects of myeloproliferative disorders. Mancini M; Diverio D; Alimena G; Mandelli F Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292 [TBL] [Abstract][Full Text] [Related]
10. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R; Rocca B; Patrono C Crit Rev Oncol Hematol; 1995 Oct; 20(3):203-22. PubMed ID: 8748010 [No Abstract] [Full Text] [Related]
14. The myelodysplastic syndromes and myeloproliferative disorders. Williams JL Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729 [TBL] [Abstract][Full Text] [Related]
15. [The liver and myeloproliferative syndromes]. Lavabre-Bertrand T; Jourdan E; Bureau JP; Blanc P Gastroenterol Clin Biol; 2002 Feb; 26(2):136-45. PubMed ID: 11938064 [No Abstract] [Full Text] [Related]
16. [Recommendations for the cytogenetic management of myeloproliferative syndromes proposed by the French Group for Cytogenetic Hematology]. Groupe Français de Cytogénétique Hématologique (GFCH) Pathol Biol (Paris); 2004 Jun; 52(5):241-4. PubMed ID: 15217703 [No Abstract] [Full Text] [Related]
17. The management of elderly patients with myeloproliferative disorders. Tura S Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340 [No Abstract] [Full Text] [Related]
18. Focus on myeloproliferative diseases and myelodysplastic syndromes. Van Etten RA; Shannon KM Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959 [No Abstract] [Full Text] [Related]
20. Acquired von Willebrand syndrome type IIA in a patient with aortic valve stenosis and myeloproliferative disorder. Gartner V; Oehler L Ann Hematol; 2006 Mar; 85(3):200-1. PubMed ID: 16237526 [No Abstract] [Full Text] [Related] [Next] [New Search]